Salud financiera de hoja de balance de Arrowhead Pharmaceuticals
Salud financiera controles de criterios 3/6
Arrowhead Pharmaceuticals tiene un patrimonio de los accionistas total de $339.0M y una deuda total de $336.0M, lo que sitúa su ratio deuda-patrimonio en 99.1%. Sus activos y pasivos totales son $883.8M y $544.8M respectivamente.
Información clave
99.1%
Ratio deuda-patrimonio
US$336.03m
Deuda
| Ratio de cobertura de intereses | n/a |
| Efectivo | US$434.47m |
| Patrimonio | US$338.97m |
| Total pasivo | US$544.79m |
| Activos totales | US$883.76m |
Actualizaciones recientes sobre salud financiera
Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) A Risky Investment?
Oct 04
Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Too Much Debt?
May 21Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Debt In A Risky Way?
Sep 19We're Not Worried About Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Cash Burn
Oct 24Recent updates
Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) A Risky Investment?
Oct 04Arrowhead Pharmaceutical: Driving To Commercialization
Jul 26Estimating The Fair Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Jun 12Arrowhead Pharmaceuticals: Hoping Something Sticks
May 27Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Too Much Debt?
May 21Arrowhead Pharmaceuticals: Focus Turns To Upcoming Pipeline Inflection Point
May 17Some Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shareholders Look For Exit As Shares Take 27% Pounding
Apr 03Arrowhead: RNAi Specialist Struggling To Show A Strong Hand (Rating Downgrade)
Mar 30Shareholders May Be Wary Of Increasing Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation Package
Mar 08Estimating The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Feb 19Arrowhead Pharmaceuticals: A Leading Small-Cap Developer Of RNAi Therapy
Jan 21Pinning Down Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) P/S Is Difficult Right Now
Dec 25Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Debt In A Risky Way?
Sep 19Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares Climb 25% But Its Business Is Yet to Catch Up
Apr 17Shareholders May Be More Conservative With Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation For Now
Mar 10A Look At The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Jan 24We're Not Worried About Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Cash Burn
Oct 24Arrowhead Pharmaceuticals: Emerging From The 'Data Desert' With A Flood Of Opportunities
Sep 12Johnson & Johnson And Arrowhead Pharmaceuticals Could Have Big News Coming
Aug 23Arrowhead seeks New Zealand regulator nod to start trial of ARO-MMP7 for lung disease
Aug 17Arrowhead Pharmaceuticals: An RNAi Name To Know
Jul 28Arrowhead Pharmaceuticals names internal officer as new COO
Jul 20Arrowhead begins dosing in early-stage studies of 2 potential lung disease drugs
Jul 05Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($450.1M) de ARWR superan a sus pasivos a corto plazo ($96.7M).
Pasivo a largo plazo: Los activos a corto plazo de ARWR ($450.1M) superan a sus pasivos a largo plazo ($448.1M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: ARWR tiene más efectivo que su deuda total.
Reducción de la deuda: El ratio deuda-patrimonio de ARWR ha crecido de 0% a 99.1% en los últimos 5 años.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: ARWR tiene menos de un año de cash runway basado en su flujo de caja libre actual.
Pronóstico de cash runway: ARWR tiene menos de un año de cash runway si el flujo de caja libre sigue reduciéndose a tasas históricas de 47% cada año